Comparison of Bioactive Proteins in Platelet-Rich Plasma (PRP) Obtained from Gel Particles and Non-Gel Particles by using a Commercial Centrifuge Column kit
Keywords:Platelet-rich Plasma, Selphyl, Dermalink Thailand, Mesoprase-20, Celtac Thailand
Evaluation of bioactive proteins in platelet-rich plasma after preparation, by using commercial centrifuge kits. Peripheral blood samples were drawn from 5 healthy male donors, aged 20-30 and processed with 2 types of commercial centrifugation column kits; a gel separator column kit (Selphyl, Dermalink Thailand) and a non-gel separator column kit (Mesoprase-20, Celtac Thailand). The completed blood count was measured by an automated machine. Additionally, the bioactive proteins were examined with the help of a cytokine chemokine profile and inflammatory marker such as: Platelet-derived growth factor-BB (PDGF-BB), Epidermal growth factor (EGF), Fibroblast growth factor-2 (FGF-2), Hepatocyte Growth factor (HGF) and Interleukin-8 (IL-8). All results were analysed by the Magnetic Bead Immuno Chemiluminescence Assay method by Luminex magpix (Merck, Thailand). The results indicated that white blood cells in Selphyl showed significant differences in comparison to Mesoprase-20 values (mean, 0.05 vs. 0.10, p=0.028)., whereas the values of red blood cells and platelets showed no considerable deviations for both centrifuge kits. The cytokine chemokine profile and inflammatory marker analysis indicated no significant differences, except for EGF and FGF-2. When we compared the levels of EGF and FGF-2 with the ones of the recovered platelets, it became evident that these did not correlate with the concentration of platelets. The platelets count isolated from Sephyl was lower than from Mesoprase-20 (210.6 ± 58.95 vs. 261.8 ± 67.58 respectively, p = 0.140), other than the FGF-2 level that turned out to be higher (137.17±11.77 vs. 127.28±13.89, p = 0.034). When we considered the EGF level, both PRP Kits correlated with platelets count (261.80±126.7 vs. 392.10±158.72, p = 0.040). The experiment showed that Selphyl is more efficient than Mesoprase-20 when isolating PRP with less white blood cells. Regardless, red blood cells, platelets and bioactive proteins showed slightly significant differences as compared to Mesoprase-20. It also became evident that Selphyl was more useful, practical, convenient and completely closed systemic when collecting and isolating PRP from whole blood. However, the variation of bioactive proteins in platelet-rich plasma depended on individual variations as it directly affected the quality of platelet-rich plasma.
Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55: 1294-9.
Lee JW, Kwon OH, Kim TK, Cho YK, Choi KY, Chung HY, et al. Platelet-rich plasma: quantitative assessment of growth factor levels and comparative analysis of activated and inactivated groups. Arch Plast Surg 2013; 40 : 530-5.
Pochini AC, Antonioli E, Bucci DZ, Sardinha LR, Andreoli CV, Ferretti M, et al. Analysis of cytokine profile and growth factors in platelet-rich plasma obtained by open systems and commercial columns. Einstein (Sao Paulo) 2016; 14: 391-7.
Latalski M, Elbatrawy YA, Thabet AM, Gregosiewicz A, Raganowicz T, Fatyga M, et al. Enhancing Bone Healing During distraction osteogenesis with platelet-rich plasma. Injury 2011; 42: 821-4.
Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. The systemic effects of platelet-rich plasma injection. Am J Sports Med 2013; 41: 186-93.
Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39: 2135-40.
Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006; 24: 227-34.
Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyteand platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27: 158-67.
de Jonge S, de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med 2011; 39: 1623–29.
Taniguchi Y, Yoshioka T, Sugaya H, Gosho M, Aoto K, Kanamori A, et al. Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop 2019; 6: 4.
Xiong G, Lingampalli N, Koltsov JCB, Leung LL, Bhutani N, Robinson WH, et al. Men and Women Differ in the Biochemical Composition of Platelet-Rich Plasma. Am J Sports Med. 2018; 46: 409-19.
Ugur MG, Kutlu R, Kilinc I. The effects of smoking on vascular endothelial growth factor and inflammation markers: A case-control study. Clin Respir J 2018; 12: 1912-18.
Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy 2012; 28: 429-39.
Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-8.
Bowen RA, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med (Zagreb) 2014; 24: 31–44.
Keever-Taylor CA, Schmidt K, Zeng H, Morris D, Heidtke S, Konings S. et al. Determination of the volume of HPC, apheresis products based on weight in grams. Blood. 2014 ; 124 : 3850
Rhoades RA, Bell DR. In: Taylor C, Horvath K. Medical Physiology Principles for Clinical Medicine. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2009.p. 169-87.
Ben-Ezra J, Sheibani K, Hwang DL, Lev-Ran A. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets. Am J Pathol 1990; 137: 755-9.
How to Cite
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์